GoAI
Get started
NewcelX Ltd. logo

NewcelX Ltd.

NCEL

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.2627

−$0.1073 · -3.18%

Aug 21, 4:00 PM ET

Pre-market

$3.4524

+$0.1897 · +5.81%

Aug 24, 4:25 AM ET

NCEL company overview

Historical prices · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

36

Expensive

Momentum

43

Neutral

Sentiment

60

Mixed

Risk resilience

29

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CH
CEO
Ronen Twito
Listed since
Oct 24, 2025
Employees
11

Market position

Day range

Current $3.2627

52-week range

Current $3.2627

Open
$3.31
Previous close
$3.37
Volume
1.39K
0.03× average
Average volume
44.09K
Average daily volume
Market cap
1.47M USD
Beta
0.93
Market reference 1
50-day average
$3.5873
-9.05% below average
200-day average
$3.1405
+3.89% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
5.46M USD
EV / EBITDA
-2.44×
Earnings yield
-113.64%
Free cash flow yield
-37.98%

Profitability & efficiency

Return on equity
-114.48%
Return on assets
-72.52%
Return on invested capital
-32.53%

Financial health

Current ratio
0.76×

Financial statements

Income trends

Operating income

−2.47M USD+43.52%

Net income

−8.3M USD-319.02%
Income trends across reported periods−529.32K USD−6.34M USD−12.14M USD−17.95M USDOperating income, FY2021: −11.86M USDOperating income, FY2022: −15.48M USDOperating income, FY2023: −11.81M USDOperating income, FY2024: −4.38M USDOperating income, FY2025: −2.47M USDNet income, FY2021: −11.95M USDNet income, FY2022: −16.5M USDNet income, FY2023: −12.17M USDNet income, FY2024: −1.98M USDNet income, FY2025: −8.3M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −11.86M USD. Operating income FY2022 −15.48M USD. Operating income FY2023 −11.81M USD. Operating income FY2024 −4.38M USD. Operating income FY2025 −2.47M USD. Net income FY2021 −11.95M USD. Net income FY2022 −16.5M USD. Net income FY2023 −12.17M USD. Net income FY2024 −1.98M USD. Net income FY2025 −8.3M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold—3.32K USD11.41K USD11.41K USD10.05K USD
Gross profit—−3.32K USD−11.41K USD−11.41K USD−10.05K USD
Research and development1.13M USD422.05K USD5.91M USD8.98M USD5.92M USD
Selling, general, and administrative1.35M USD3.21M USD5.9M USD6.49M USD5.93M USD
Operating expenses2.47M USD4.38M USD11.81M USD15.47M USD11.85M USD
Interest income369K USD——100.87 USD68.13 USD
Interest expense6.01M USD150.02K USD145.15K USD100.87K USD68.13K USD
Depreciation and amortization55K USD3.32K USD11.41K USD11.41K USD10.05K USD
Operating income−2.47M USD−4.38M USD−11.81M USD−15.48M USD−11.86M USD
Net income−8.3M USD−1.98M USD−12.17M USD−16.5M USD−11.95M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
67%
2 beats, 0 misses, 1 met estimate
Average EPS surprise
+65.31%
3 comparable reports
Latest EPS result
1.29

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates10.99-35.91-82.8-129.7Q2 '23BeatQ4 '23MetQ2 '24BeatQ4 '24No estimateQ2 '25No estimateQ4 '25No estimateQ1 '26No estimateQ3 '26Estimate
Q2 2023, reported May 5, 2023: actual -2.9, estimate -120, surprise +97.58%, Beat. Q4 2023, reported Dec 6, 2023: actual -68, estimate -68, surprise 0.00%, Met estimate. Q2 2024, reported May 15, 2024: actual -1.4, estimate -84, surprise +98.33%, Beat. Q4 2024, reported Oct 18, 2024: actual -1.94, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 16, 2025: actual -26.3, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Oct 4, 2025: actual -10.5, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 25, 2026: actual 1.29, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Sep 2, 2026: actual —, estimate -0.53, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Oct 31, 2025

1:10

Stock split

Effective Sep 27, 2024

1:40

NCEL peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research NCEL

research.disclaimer